Leading Pharmaceutical and Dermo-cosmetics Group Replaces Most of its Existing Product Development Applications with Single PLM Platform;
Develop more cross-cutting activities, improve time to market and improve product traceability

PARIS (European Customer Forum), November 22, 2011 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA), a world leader in 3D and Product Lifecycle Management (PLM) solutions, today announced that Pierre Fabre Laboratories has selected its ENOVIA Version 6 solution as its PLM platform. Delivering an up-to-the-minute, enterprise-wide vision of raw material and substance flows, as well as all associated regulatory documents and data, Dassault Systèmes’ Version 6 platform will support the international expansion of Pierre Fabre Médicament (pharmaceuticals), Pierre Fabre Santé (family health) and Pierre Fabre Dermo-cosmétique (dermo-cosmetics).

Deployment will be phased in over the next four years. ENOVIA has already been successfully implemented to manage Pierre Fabre Laboratories' global dermo-cosmetics product portfolio, including formulas, raw materials, substances and country-specific products. As the backbone of this transformation, ENOVIA provides the enterprise-wide repository for full lifecycle product-related information, facilitating real-time collaboration and decision-making among all departments – from purchasing and development to regulatory affairs, quality assurance, affiliates and partners.

"Developing and marketing drugs, family health and dermo-cosmetic products involves complex processes, which are subject to compliance with strict patient and consumer safety regulations. Traceability is the watchword in all processes and decision-making," said Sylvie Touya, head of Strategic Programs, Pierre Fabre Laboratories. “Configured to the requirements of each phase involved in these three core businesses, PLM will enable us to achieve maximum traceability. As well as optimizing processes, PLM will help us achieve our goals of accelerating time to market, improving compliance, expanding internationally and driving innovation.”

"The partnership between our two companies illustrates Dassault Systèmes’ strong commitment to the life sciences industry," said Jean Colombel, vice president, Life Sciences industry, Dassault Systèmes. "As a centralized collaborative repository, ENOVIA Version 6 provides the common platform that companies need to ease collaboration across their organization and achieve their strategic innovation, compliance management and IP capitalization objectives."

###

About Pierre Fabre Laboratories

Pierre Fabre Laboratories, the second largest independent pharmaceutical laboratory in France, posted revenue of €1.86 billion in 2010, with international sales accounting for more than 50%. The company employs around 10,000 people, including 1,300 in R&D. Business spans pharmaceutical drugs, OTC family health and dermo-cosmetics (including brands like Avène, A-Derma, Ducray, Elancyl, Galénic, Glytone, Klorane and René Furterer). In 2010, Pierre Fabre Laboratories invested 22% of annual revenue from its pharmaceutical drug business in R&D, focusing on three main areas: oncology, central nervous system and dermatology.

About Dassault Systèmes

As a world leader in 3D and Product Lifecycle Management (PLM) solutions, Dassault Systèmes brings value to more than 130,000 customers in 80 countries. A pioneer in the 3D software market since 1981, Dassault Systèmes applications provide a 3D vision of the entire lifecycle of products from conception to maintenance to recycling. The Dassault Systèmes portfolio consists of CATIA for designing the virtual product - SolidWorks for 3D mechanical design - DELMIA for virtual production - SIMULIA for virtual testing - ENOVIA for global collaborative lifecycle management, EXALEAD for search-based applications and 3DVIA for online 3D lifelike experiences. For more information, visit http://www.3ds.com.

CATIA, DELMIA, ENOVIA, EXALEAD, SIMULIA, SolidWorks and 3D VIA are registered trademarks of Dassault Systèmes or its subsidiaries in the US and/or other countries.